Global Health Catalyst Summit 2017.

Global Health Catalyst Summit 2017.

April 2017, the Cannabis Science team participated in the 2017 Global Health Catalyst Summit held at Harvard Medical School in Boston, MA. The Global Health Catalyst (GHC) summit at Harvard, is a premier yearly event designed to catalyze high impact international collaborations to eliminate global health disparities, with main focus on cancer and related diseases. Mr. Dabney was the keynote speaker and panelist for a special session on “Cannabis Science Versus Cancer and Other Malignancies”.

Mr. Dabney discussed how cannabinoids can be used to treat cancer and other diseases, manage the side effects of cancer treatment like radiotherapy and chemotherapy, and potential applications of medical cannabis in global health to close the global pain divide; Cannabis Science’s vision for the global health and development impact of cannabinoid-based medicines; and the need for greater public education on the importance of medical cannabis research. Additionally, Mr. Dabney presented summit participants with an overview of the company's drug development program, as well as with an update on Cannabis Science's Collaborative Research Agreement (CRA) with Dana-Farber Cancer Institute (Dana-Farber). Dr. Allen Herman, Chief Medical Officer (CMO) of CBIS, Inc. Co-Chaired this session and participated in the discussion on the epidemiology of cancer and the utilization of opioids in Africa, which reflects the pain divide. Mr. Dabney and Dr. Herman lead CBIS’ collaboration with DFCI.

This conference afforded Cannabis Science an opportunity to discuss cutting-edge cannabinoid research with some of the greatest minds in modern medicine globally, as well as to network and explore potential partnerships. In addition, through participation in this Summit, Cannabis Science gave updates on progress in the implementation of Cannabis Science's research agreement with Dana-Farber and a potential consortium agreement involving other institutions.